Execution Under Decay: Why Most Radiopharma CDMOs Will Fail – And Who Might Succeed
The global radiopharmaceutical market is in the midst of a “gold rush,” a period of explosive growth fueled by the clinical and commercial success of radioligand therapies (RLTs). This momentum, marked by staggering multi-billion-dollar M&A deals and soaring investment, has created unprecedented opportunity. However, this financial fervor is running headlong into critical constraints: underdeveloped manufacturing […]